Thrombosis of tibial arteries in a patient receiving tamoxifen therapy

Deshmukh, Narayan; Tripathi, Sanjay P.

doi:10.1002/1097-0142(19950915)76:6<1006::aid-cncr2820760614>3.0.co;2-k

Cited by 16 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Venous thromboembolism is a common vascular disorder in tamoxifen-treated breast cancer patients though arterial thrombosis in this group of patients has also been reported. 77…”

Section: Tamoxifenmentioning

confidence: 99%

Thrombophilic State in Breast Cancer

Kuhn¹,

Harbeck²,

Graeff³

1999

Semin Thromb Hemost

View full text Add to dashboard Cite

Tumor cell metastasis and thrombosis are the major causes of death in cancer patients. Thrombosis in cancer patients may occur when physiologic antithrombotic systems are defective or when prothrombotic activities defeat normal physiologic antithrombotic mechanisms. Malignancies by themselves may already predispose to a hypercoagulable state in cancer patients. Tumor cells can either directly activate the blood clotting system or indirectly stimulate mononuclear cells to synthesize and express various procoagulants, subsequently leading to prothrombin activation, fibrin formation, and generation of a thrombus. In addition, other comorbid predisposing factors effecting thrombosis in cancer patients have to be considered, including surgery, bed rest, infection, long-term indwelling central venous catheters, anticoagulation, and chemotoxic or steroidal anticancer drugs used in adjuvant or palliative cancer treatment. Reliable information on the incidence of thromboembolism in cancer patients is available for breast cancer; less data have been reported for other malignancies. Chemo- and/or hormone therapy in patients with primary or metastatic breast cancer is associated with an increased thromboembolic risk, although the benefits of treatment far outweigh the risks. The current literature discussing the effect of chemo/hormone therapy on blood clotting factors and the associated risk of thrombosis is reviewed, with emphasis on new developments in the area of tissue-specific SERMs (selective estrogen receptor modulators). SERMs are employed as adjuvant therapy in primary breast cancer and in the palliation of advanced breast cancer and may be clinically useful as potential substitutes for long-term hormone replacement therapy, in the treatment of osteoporosis, and for cancer prevention therapy.

show abstract

“…Venous thromboembolism is a common vascular disorder in tamoxifen-treated breast cancer patients though arterial thrombosis in this group of patients has also been reported. 77…”

Section: Tamoxifenmentioning

confidence: 99%

Thrombophilic State in Breast Cancer

Kuhn¹,

Harbeck²,

Graeff³

1999

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Although the majority of case-report deals with venous thrombosis, a randomized study and some case reports pointed an increased risk in the arterial thrombosis in pre-and postmenopausal women receiving tamoxifen. 7,14 The oral administration of tamoxifen is well tolerated by the animals and ensures reliable levels of medication. The pretreatment period of 2 weeks was based in the maximal life span of rats to simulate a period of chronic administration of tamoxifen.…”

Section: Discussionmentioning

confidence: 99%

“…Many clinical reports showed an increased risk of venous and arterial thrombosis in diverse vascular beds as brain and upper and lower extremity. [7][8][9] The common pathway to thrombotic and thromboembolic disease in the setting of tamoxifen therapy is not totally understood. Reduced levels of antithrombin III, and protein C and S are implicated in the genesis of vascular events.…”

mentioning

confidence: 99%

Effect of tamoxifen on arterial microvascular anastomosis

et al. 2007

View full text Add to dashboard Cite

Breast reconstruction after cancer treatment is based on the circulation of pedicle and microvascular flaps. This article aimed to verify the effect of tamoxifen (TMX) pretreatment in arterial anastomosis in rats. Twenty female Wistar rats were equally divided into two groups. TMX (0.3 mg/kg) was administered to the experimental group for 2 weeks orally. After this period, the right femoral artery was sectioned and a terminoterminal anastomosis performed. The same procedure was done in the control group, except that the animals received the vehicle without TMX. One week later, the femoral arteries were inspected for flow through the anastomosis, and the vessel near it was sent to light microscopic examination. It was observed mild vasculite in both groups. The intimal thickness and total vessel wall in the TMX-treated group was significantly higher. A real thrombotic effect upon the arterial vascular anastomosis was not observed, eventhough, TMX induced intimal hyperplasia.

show abstract

“…In rare instances, this can result in thromboembolic disease including tibial artery thrombosis, Budd-Chiari syndrome, or cerebral sinus thrombosis 1 3 4. Despite the known risk of thromboembolic disease, tamoxifen has not been reported as a cause of portal vein thrombosis.…”

Section: Introductionmentioning

confidence: 99%